Overview

Long Term Experience With Abatacept in Routine Clinical Practice

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the retention rate of Abatacept over 24 months in routine clinical practice in every participating country depending on the treatment line.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept